Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Bio-Techne Corporation reported mixed third-quarter fiscal 2026 results amid uneven end-market conditions.</li><li>Total revenue declined 2% organically and on a reported basis to $311.4 million, affected by timing of large OEM commercial supply orders and purchases from two major cell therapy customers that received FDA Fast Track Designations.</li><li>Excluding these timing effects, underlying organic growth was approximately 2%.</li></ul>

Bio-Techne Corporation reported mixed third-quarter fiscal 2026 results amid uneven end-market conditions.Total revenue declined 2% organically and on a reported basis to $311.4 million, affected by timing of large OEM commercial supply orders and purchases from two major cell therapy customers that received FDA Fast Track Designations.Excluding these timing effects, underlying organic growth was approximately 2%.

Bio-Techne's $311.4 Million Revenue Base — Biotech Recovery Could Reshape Growth!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Bio-Techne is a key 'picks and shovels' supplier for the life sciences industry, providing high-margin, recurring-revenue consumables and instruments critical for research and diagnostics.</li>
  <li>Recent financial performance has been mixed, with soft organic revenue due to challenging end-markets, particularly in emerging biotech and academia, though this is partially offset by strong, consecutive double-digit growth from large pharmaceutical clients.</li>
  <li>The company is strategically focused on high-growth areas like spatial biology, cell and gene therapy, and proteomics to drive future growth, while navigating near-term headwinds from fluctuating R&amp;D budgets and intense competition.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Bio-Techne is a key 'picks and shovels' supplier for the life sciences industry, providing high-margin, recurring-revenue consumables and instruments critical for research and diagnostics.
  Recent financial performance has been mixed, with soft organic revenue due to challenging end-markets, particularly in emerging biotech and academia, though this is partially offset by strong, consecutive double-digit growth from large pharmaceutical clients.
  The company is strategically focused on high-growth areas like spatial biology, cell and gene therapy, and proteomics to drive future growth, while navigating near-term headwinds from fluctuating R&amp;D budgets and intense competition.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Bio Techne Corp (TECH US) - Aug 2026

<ul><li>Bio-Techne Corporation reported third quarter fiscal 2026 results reflecting a mixed performance amid varied end-market dynamics.</li><li>Total revenue was $311.4 million, down 2% organically and reported, with foreign exchange providing a modest 2% tailwind and a 2% headwind from the prior Exosome Diagnostics divestiture.</li><li>Adjusted earnings per share were $0.53, slightly below the prior year by $0.03, while GAAP EPS improved to $0.32 from $0.14.</li></ul>

Bio-Techne Corporation reported third quarter fiscal 2026 results reflecting a mixed performance amid varied end-market dynamics.Total revenue was $311.4 million, down 2% organically and reported, with foreign exchange providing a modest 2% tailwind and a 2% headwind from the prior Exosome Diagnostics divestiture.Adjusted earnings per share were $0.53, slightly below the prior year by $0.03, while GAAP EPS improved to $0.32 from $0.14.

Bio-Techne’s Hidden Growth Engine: COMET Surges As Core Markets Stay Soft!

<ul><li>Bio-Techne Corporation operates in a position that enables participation across a broad range of life science and biopharma research activity.</li><li>Biotech funding rebounded in the second half of calendar 2025, which is viewed as an encouraging signal for 2026.</li><li>Historically, there has been an approximate six-month lag between funding activity and measurable increases in demand for research tools and reagents.</li></ul>

Bio-Techne Corporation operates in a position that enables participation across a broad range of life science and biopharma research activity.Biotech funding rebounded in the second half of calendar 2025, which is viewed as an encouraging signal for 2026.Historically, there has been an approximate six-month lag between funding activity and measurable increases in demand for research tools and reagents.

Bio-Techne: How Spatial Biology Innovation Is Powering a Strategic Comeback!

<ul><li>Bio-Techne delivered its first-quarter fiscal year 2026 results amidst a challenging market environment.</li><li>Despite the company’s strategic and disciplined efforts, organic revenue declined by 1%, primarily due to timing issues in their Cell Therapy business from large customers and the ongoing softness in biotech funding.</li><li>These timing issues were particularly impacted by FDA Fast Track Designations received by key customers that, while accelerating therapy approval timelines, reduced the near-term demand for reagents.</li></ul>

Bio-Techne delivered its first-quarter fiscal year 2026 results amidst a challenging market environment.Despite the company’s strategic and disciplined efforts, organic revenue declined by 1%, primarily due to timing issues in their Cell Therapy business from large customers and the ongoing softness in biotech funding.These timing issues were particularly impacted by FDA Fast Track Designations received by key customers that, while accelerating therapy approval timelines, reduced the near-term demand for reagents.

Bio-Techne Braces for a Biotech Funding Revival—Is a Major Upswing Ahead?

United States

Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio Techne Corp (TECH US)

Bio-Techne's $311.4 Million Revenue Base — Biotech Recovery Could Reshape Growth!

Bio-Techne Corporation reported mixed third-quarter fiscal 2026 results amid uneven end-market conditions. Total revenue declined 2% organically...

Baptista Research

Primer: Bio Techne Corp (TECH US) - Aug 2026

Bio-Techne is a key 'picks and shovels' supplier for the life sciences industry, providing high-margin, recurring-revenue consumables and...

αSK Primers

Bio-Techne’s Hidden Growth Engine: COMET Surges As Core Markets Stay Soft!

Bio-Techne Corporation reported third quarter fiscal 2026 results reflecting a mixed performance amid varied end-market dynamics. Total revenue...

Baptista Research

Bio-Techne: How Spatial Biology Innovation Is Powering a Strategic Comeback!

Bio-Techne Corporation operates in a position that enables participation across a broad range of life science and biopharma research...

Baptista Research

Bio-Techne Braces for a Biotech Funding Revival—Is a Major Upswing Ahead?

Bio-Techne delivered its first-quarter fiscal year 2026 results amidst a challenging market environment. Despite the company’s strategic and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)